Allogenic Delta One T cells expressing a CD123-CAR (Vδ1 γδ T cells) showed potent in vitro and in vivo killing of AML blasts and maintained activity upon tumor rechallenge [109], while allogenic γδ CD33-CAR-T cells from healthy donors demonstrated rapid cytotoxicity, prolonged metabolic fitness, and superior in vivo anti-AML activity compared with conventional αβ CAR-T cells [110]. This evidence concerns the gene CD33 and acute myeloid leukemia.